MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:33Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antimuscarinics]]
			[[Category:Overactive bladder medications]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #114

2026-05-23T03:46:16Z

parser-claude batch MedTemplate pre-fill, Top 300 #114

New page

{{MedTemplate
| generic = Oxybutynin
| brand = Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel)
| structure =
| classes = [[:Category:Antimuscarinics|Antimuscarinic]], [[:Category:Overactive_bladder_medications|Overactive bladder medication]]
| uses = <vote slug="overactive-bladder-use">Overactive bladder (urgency, frequency, urge incontinence)</vote>, <vote slug="neurogenic-bladder-use">Neurogenic detrusor overactivity</vote>, <vote slug="hyperhidrosis-use">Hyperhidrosis (off-label)</vote>
| starting_dose = IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC)
| preparations = 5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel
| fda_max = 30 mg/d (XL) typical
| pill_id =
| routes = Oral, transdermal, topical gel, intravesical
| onset = 30-60 minutes (PO)
| duration = IR: 6-10 hours; ER: 24 hours
| halflife = 2-3 hours (parent and active N-desethyl metabolite)<ref name="ditropan-label">FDA Prescribing Information, Ditropan XL (oxybutynin chloride), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020897s039lbl.pdf</ref>
| bioavailability = ~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated<ref name="ditropan-label" />
| pregnancy = Limited data.{{citation needed}}
| legal = OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US
| mechanism = <vote slug="oxybutynin-mech-claim">Oxybutynin is a non-selective muscarinic receptor antagonist with predominant M3 antagonism in the detrusor, relaxing involuntary contractions and increasing functional bladder capacity.</vote> Lack of M3 selectivity drives the characteristic anticholinergic burden (dry mouth, constipation, blurred vision, urinary retention, CNS effects in elderly). Cumulative anticholinergic exposure is implicated in dementia risk in older adults, which is a growing reason to prefer β3-agonists (mirabegron) or M3-selective antimuscarinics in that population<ref name="ditropan-label" />.
}}

== References ==
<references />

Oxybutynin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #114